Novo Nordisk’s type 2 diabetes drug Ozempic has expanded its label to include chronic kidney disease. The new FDA approval comes as makers of GLP-1 drugs work to expand the uses of these products.
The post New FDA Approval Adds Chronic Kidney Disease to Ozempic’s Label appeared first on MedCity News.
